Rx License-Rx

23-10336-TpNCS

Pyrazole Derivatives for the Treatment of Lung Cancer Tumors

A class of pyrazole derivatives that inhibit palmitoyl-transferases, resulting in increasing cancer cell responsiveness to epidermal growth factor receptor inhibitor and KRas mutant lung cancer growth inhibition as a single agent. Problem: Pancreatic and lung cancers are largely driven by either Epidermal growth factor receptor (EGFR) mutation KRAS mutations. However current therapies targeting either of these mutated proteins are either unavailable (KRas G12S/D/V/R) or rapidly develop resistance mutations (EGFR, KRas G12C). No targeted therapeutic options exist for mutant KRAS G12S/D/V/R tumors, making treatment of these cancers difficult and dependent on conventional chemotherapy and radiation. Solution: Pyrazole derivatives that increase sensitivity to EGFR inhibitors by creating a dependency on EGFR signaling for cancer cell survival, increasing responsiveness to EGFR inhibitor therapy. Additionally, the increase in EGFR signaling...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Lung cancer

Modality: Small Molecule

Focus tags: Oncology

Technology tags: Small Molecule, Biologic, Diagnostic / Biomarker, Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: PCT Filed

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Lung cancer. Public description: A class of pyrazole derivatives that inhibit palmitoyl-transferases, resulting in increasing cancer cell responsiveness to epidermal growth factor receptor inhibitor and KRas mutant lung cancer growth inhibition as a single agent. Problem.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Lung cancer

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.